Dexamethasone Phosphate

ApprovedSmall molecule

Dexamethasone Phosphate is one of 154 small molecule programs targeting Systemic Inflammatory Response Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

153

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Inflammatory Response SyndromeActive, not recruiting

AppendicitisActive, not recruiting

Hearing LossActive, not recruiting

Non-Infectious Anterior UveitisActive, not recruiting

SciaticaActive, not recruiting

ScleritisActive, not recruiting

HysterectomyActive, not recruiting

CataractActive, not recruiting

Neonatal Respiratory DistressActive, not recruiting

Systemic Inflammatory Response SyndromeApproved

Active, not recruiting

AppendicitisPhase 2

Active, not recruiting

Hearing LossApproved

Active, not recruiting

Non-Infectious Anterior UveitisPhase 3

Active, not recruiting

SciaticaPhase 3

Active, not recruiting

ScleritisPhase 1

Active, not recruiting

HysterectomyPreclinical

Active, not recruiting

CataractPhase 3

Active, not recruiting

Neonatal Respiratory DistressApproved

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Approved

1 2

Kenalog

BBausch Health Americas, Inc.

Phase 3

4 3

Avastin

BBio-Thera Solutions

Phase 3

1 4

Floxin

WWim Janssens

Phase 3

1 5

Isopto Carpine

AAdvanz Pharma

Phase 3

1 6

Aquasol E

NNational Eye Institute (NEI)

Zolymbus

Neurontin

VViatris Specialty LLC

Preclinical

3 9

Kenalog

BBassett Healthcare

Preclinical

1 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Cataract

NCT07305987

Q4 2026

Post-ApprovalRecruiting

Dexmedetomidine

NCT05793060

Q1 2028

N/ARecruiting

Cardiac Surgery

NCT05635227

Clinical

Trials by Indication[1]

Safety and Efficacy3 trials

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

Completed·EEyegate Pharmaceuticals, Inc.·Phase 3·NCT01129856·198 enrolled

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL

Completed·EEyegate Pharmaceuticals, Inc.·Phase 2·NCT01602068·45 enrolled

Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema

Terminated·EEyegate Pharmaceuticals, Inc.·Phase 1/2·NCT02485249·25 enrolled

Dexamethasone2 trials

PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy

Completed·EEyegate Pharmaceuticals, Inc.·Phase 1·NCT02644694·10 enrolled

Perineural Dexamethasone in Femural Nerve Block After Ligament Reconstruction

Completed·FFoisor Orthopedics Clinical Hospital·Phase 3·NCT02749162·90 enrolled

Hearing Loss2 trials

Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment

Completed·MMeir Medical Center·Phase 4·NCT01372904·30 enrolled

Sudden Hearing Loss Multi-center Clinical Trial

Unknown status·PPeking University People's Hospital·N/A·NCT02026479·300 enrolled

Dexmedetomidine1 trial

Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block

Recruiting·—·Phase 4·NCT05793060·60 enrolled

Systemic Inflammatory Response Syndrome1 trial

Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome

Completed·—·Phase 4·NCT03876041·60 enrolled

11 more indications

Scleritis1 trial

Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

Completed·JJohn Kempen·Phase 1·NCT01059955·18 enrolled

Non-Infectious Anterior Uveitis1 trial

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

Completed·EEyegate Pharmaceuticals, Inc.·Phase 3·NCT02517619·251 enrolled

Sciatica1 trial

Efficacy of Soluble Dexamethasone in Refractory Sciatica

Completed·NNantes University Hospital·Phase 3·NCT05000658·109 enrolled

Appendicitis1 trial

Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis

Completed·NNordsjaellands Hospital·Phase 2·NCT02415335·119 enrolled

Mastectomy1 trial

Effectiveness of Combined Erector Spinae and Pecto-intercostal Fascial Plane Blocks Versus Thoracic Paravertebral Block in Perioperative Pain in Modified Radical Mastectomy

Completed·KKasr El Aini Hospital·Phase 4·NCT04778267·30 enrolled

Spinal Anesthesia1 trial

Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering

Completed·—·Phase 4·NCT03675555·300 enrolled

Neonatal respiratory distress1 trial

Dexamethasone Before Elective Cesarean Section at Term in Reducing Neonatal Respiratory Distress Syndrome

Unknown status·—·Phase 4·NCT04816097·950 enrolled

Cardiac Surgery1 trial

Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery

Recruiting·RRigshospitalet, Denmark·N/A·NCT05635227·1,200 enrolled

Orthopedic Surgeries1 trial

Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries

Completed·—·Phase 4·NCT03664037·110 enrolled

Hysterectomy1 trial

Dexamethasone and Robotic-assisted Hysterectomy

Completed·—·N/A·NCT04762381·109 enrolled

Cataract1 trial

PRO-232 in Patients Subjected to Cataract Surgery

Recruiting·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT07305987·134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Dexamethasone Phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexamethasone Phosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexamethasone Phosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eyegate Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEyegate Pharmaceuticals, Inc.

Dexamethasone Phosphate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2028

Trials by Indication[1]

Safety and Efficacy3 trials

Dexamethasone2 trials

Hearing Loss2 trials

Dexmedetomidine1 trial

Systemic Inflammatory Response Syndrome1 trial

Scleritis1 trial

Non-Infectious Anterior Uveitis1 trial

Sciatica1 trial

Appendicitis1 trial

Mastectomy1 trial

Spinal Anesthesia1 trial

Neonatal respiratory distress1 trial

Cardiac Surgery1 trial

Orthopedic Surgeries1 trial

Hysterectomy1 trial

Cataract1 trial

References

Drug Info

Quick Facts

Related News